Ideaya Biosciences Inc (IDYA) financials
Ideaya Biosciences revenue and earnings by year
Ideaya Biosciences's revenue was $219 million in the fiscal year to December 31, 2025, up 3024.4% from the year before. Net income was -$114 million, -52.0% of revenue. Since the fiscal year to December 31, 2020, revenue has grown 62.1% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 6 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
| Revenue | 219 | 7 | 23 | 51 | 28 | 20 |
| Revenue growth | 3024.4% | -70.1% | -54.1% | 82.3% | 43.0% | — |
| Operating income | -159 | -327 | -134 | -63 | -50 | -35 |
| Operating margin | -72.8% | -4671.1% | -574.9% | -122.7% | -179.9% | -180.9% |
| Net income | -114 | -274 | -113 | -59 | -50 | -34 |
| Net margin | -52.0% | -3921.1% | -483.0% | -115.2% | -178.1% | -176.6% |
| Diluted EPS | -$1.28 | -$3.36 | -$1.96 | -$1.42 | -$1.41 | -$1.49 |
| Free cash flow | -73 | -251 | -118 | -91 | -58 | 55 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open IDYA in Markets.
See also: IDYA returns
No forecast, no recommendation. This page describes Ideaya Biosciences Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.